Results 1 to 10 of about 19,663 (194)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort

Current Oncology, 2022
The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review.
Amanda J. W. Gibson, Adrian Box, Winson Y. Cheung, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, Dafydd Gwyn Bebb   +8 more
doaj   +2 more sources

Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging

Pharmaceuticals, 2022
Crizotinib is a tyrosine kinase inhibitor approved for the treatment of non-small-cell lung cancer, but it is inefficient on brain metastases. Crizotinib is a substrate of the P-glycoprotein, and non-invasive nuclear imaging can be used to assess the ...
Malvika Sardana, Louise Breuil, Sébastien Goutal, Maud Goislard, Mikhail Kondrashov, Etienne Marchal, Florent L. Besson, Christophe Dugave, Gail Wrigley, Anna C. Jonson, Bertrand Kuhnast, Magnus Schou, Nicolas Tournier, Charles S. Elmore, Fabien Caillé   +14 more
doaj   +2 more sources

Aseptic inflammatory abscesses induced by crizotinib in a case report of ALK rearrangement lung adenocarcinoma [PDF]

Frontiers in Oncology
BackgroundAdverse events induced by crizotinib treatment for lung adenocarcinoma are increasingly reported, with nephritic inflammatory abscesses accounting for only 4% of documented cases.
Hongyin Huang, Keke Wang, Xu Zhai, Pu Cheng, Haihong Li, Wen Qiu, Tong Peng, Leilei Cao, Qizhi Luo, Zilong Wang   +9 more
doaj   +2 more sources

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells

Pharmaceuticals, 2021
Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients.
Joelle C. Boulos, Mohamed E. M. Saeed, Manik Chatterjee, Yagmur Bülbül, Francesco Crudo, Doris Marko, Markus Munder, Sabine M. Klauck, Thomas Efferth   +8 more
doaj   +2 more sources

First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer

Cancer Medicine, 2020
Objectives Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001.
Ding Ding, Shun Lu, Lan Shen
exaly   +2 more sources

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Frontiers in Oncology, 2022
Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with
Woo Kyung Ryu, Hyungkeun Cha, Mi Hwa Park, Jung Soo Kim, Jeong-Seok Choi, Lucia Kim, Kyung-Hee Lee, Hae-Seong Nam   +7 more
doaj   +1 more source

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway

Frontiers in Pharmacology, 2021
Considerable attention has been raised on crizotinib- and sunitinib-induced hepatotoxicity, but the underlying mechanisms need further examination. In addition, limited therapeutic strategies exist to reduce the liver damage caused by crizotinib and ...
Lin Guo, Hui Gong, Ting-Li Tang, Bi-Kui Zhang, Lei-Yi Zhang, Miao Yan   +5 more
doaj   +1 more source

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Journal of Translational Medicine, 2022
Background The identification of early plasma biomarkers for clinical outcomes and drug resistance has key importance for risk stratification in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients.
Shasha Wang, Ning Lou, Rongrong Luo, Xuezhi Hao, Yutao Liu, Lin Wang, Yuankai Shi, Xiaohong Han   +7 more
doaj   +1 more source

Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.

PLoS ONE, 2015
As a promising target for the treatment of lung cancer, the MutT Homolog 1 (MTH1) protein can be inhibited by crizotinib. A recent work shows that the inhibitory potency of (S)-crizotinib against MTH1 is about 20 times over that of (R)-crizotinib.
Yuzhen Niu, Dabo Pan, Danfeng Shi, Qifeng Bai, Huanxiang Liu, Xiaojun Yao   +5 more
doaj   +1 more source

Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma [PDF]

Journal of Clinical and Diagnostic Research, 2016
The presence of an ALK (Anaplastic Lymphoma Kinase) rearrangement is a rare molecular feature in Non-Small Cell Lung Carcinoma (NSCLC), and concerns mainly non- or light smokers, young patients, with adenocarcinoma histological type.
Elodie Mussat, Violaine Giraud, Catherine Julie, Thierry Chinet, Etienne Giroux Leprieur   +4 more
doaj   +1 more source